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Hox-C9 activates the intrinsic pathway of apoptosis
and is associated with spontaneous regression in
neuroblastoma
H Kocak1, S Ackermann1, B Hero1, Y Kahlert1, A Oberthuer1, D Juraeva2, F Roels1, J Theissen1, F Westermann3, H Deubzer4,
V Ehemann5, B Brors2, M Odenthal6, F Berthold1 and M Fischer*,1
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system. Spontaneous regression and differentiation of
neuroblastoma is observed in a subset of patients, and has been suggested to represent delayed activation of physiologic
molecular programs of fetal neuroblasts. Homeobox genes constitute an important family of transcription factors, which play a
fundamental role in morphogenesis and cell differentiation during embryogenesis. In this study, we demonstrate that expression
of the majority of the human HOX class I homeobox genes is significantly associated with clinical covariates in neuroblastoma
using microarray expression data of 649 primary tumors. Moreover, a HOX gene expression-based classifier predicted
neuroblastoma patient outcome independently of age, stage and MYCN amplification status. Among all HOX genes, HOXC9
expression was most prominently associated with favorable prognostic markers. Most notably, elevated HOXC9 expression was
significantly associated with spontaneous regression in infant neuroblastoma. Re-expression of HOXC9 in three neuroblastoma
cell lines led to a significant reduction in cell viability, and abrogated tumor growth almost completely in neuroblastoma
xenografts. Neuroblastoma growth arrest was related to the induction of programmed cell death, as indicated by an increase in
the sub-G1 fraction and translocation of phosphatidylserine to the outer membrane. Programmed cell death was associated with
the release of cytochrome c from the mitochondria into the cytosol and activation of the intrinsic cascade of caspases, indicating
that HOXC9 re-expression triggers the intrinsic apoptotic pathway. Collectively, our results show a strong prognostic impact of
HOX gene expression in neuroblastoma, and may point towards a role of Hox-C9 in neuroblastoma spontaneous regression.
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Class I homeobox (Hox) transcription factors constitute an
important family of developmental regulators, which play a
fundamental role in morphogenesis and cell differentiation
during embryogenesis.1 In neural progenitors, HOX gene
expression is controlled by retinoic acid (RA), fibroblast
growth factors and wingless-type family members.2,3 A
deregulated expression of HOX genes has been observed
in a number of malignancies.4–7
Neuroblastoma, an embryonal tumor of the sympathetic
nervous system, originates from primordial neural crest cells,
which are destined for sympathetic differentiation. This
pediatric solid tumor shows remarkable variations in clinical
presentations ranging from aggressive, therapy-resistant
progression to spontaneous regression, which regularly
occurs in infants both with localized and metastasized
disease. Furthermore, neuroblastoma cells show the potential
to differentiate toward a sympathetic ganglion cell phenotype.8
It has thus been suggested that the physiologic molecular
program of neuroblast differentiation and growth control is
disrupted in neuroblastoma.9 This developmental arrest may
be reversible in spontaneously regressing neuroblastoma, in
which a delayed activation of naturally occurring processes
of programmed cell death has been suspected.10–12
According to its embryonic nature, many genes aberrantly
expressed in neuroblastoma are involved in developmental
processes.13,14 Among others, several transcription factors
involved in the development of autonomic neural crest
derivates, such as MYCN and PHOX2B, are implicated
in the pathogenesis of neuroblastoma.15–18 Furthermore,
various HOX genes have been described to be aberrantly
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expressed in neuroblastoma cell lines and primary tumors.19,20
In a recent study,Mao et al.21 reported thatHOXC9 expression
is decreased in advanced-stage neuroblastoma and is
involved in cell cycle control and the processes of neuroblas-
toma cell differentiation.
In this study, we aimed at determining the association of
class I HOX gene expression patterns with prognostic
markers and outcome in neuroblastoma. Because HOXC9
was not only associated with favorable outcome but also with
spontaneous regression, we investigated the functional
consequences of HOXC9 re-expression on neuroblastoma
growth and programmed cell death.
Results
Expression of the HOX gene cluster is deregulated in
neuroblastoma. The expression patterns of the 39 class I
HOX genes were analyzed in 649 neuroblastoma samples by
microarrays, and the association with prognostic markers
and patient outcome was determined. The expression of the
majority of HOX genes correlated significantly with clinical
covariates in neuroblastoma. Elevated expression of HOXD
genes, particularly HOXD3, HOXD8, HOXD9 and HOXD10,
was predominantly associated with unfavorable prognostic
markers and poor outcome (Supplementary Table S1
and Supplementary Figures S1 and S2). Similarly, we
observed increased expression levels of more posterior
HOX genes (HOXA10, HOXA11, HOXA13, HOXC12 and
HOXC13) in neuroblastomas with unfavorable characteristics
(Supplementary Table S1). In contrast, elevated expression
of the majority of the remaining HOX genes was significantly
correlated with favorable prognostic markers (Supplementary
Table S1).
Prediction of neuroblastoma outcome based on a HOX
gene expression signature. To assess the impact of HOX
gene expression on neuroblastoma outcome, we developed
a HOX gene expression-based classifier (Table 1a and
Supplementary Table S2) using a training cohort of 75
neuroblastoma patients with maximal divergent outcome. In
the training set, the classification accuracy was 85% as
assessed by cross-validation. In a validation subset of 215
patients who matched the outcome criteria of the training set,
the 33 HOX gene signature predicted patient outcome with
an accuracy of 76% (Table 1b). In the entire validation set
(n¼ 574), the classifier accurately discriminated patients
with favorable and unfavorable outcome (favorable: n¼ 265;
5-year event-free survival (EFS), 80.7±2.6%; 5-year
overall survival (OS), 96.0±1.2%; unfavorable: n¼ 309;
5-year EFS, 49.5±3.0%; 5-year OS, 67.1±2.8%; both
Po0.001). In multivariate Cox regression models based on
EFS and OS, the HOX classifier predicted patient outcome
independently of age, stage and MYCN amplification
status (Table 1c).
Elevated HOXC9 expression is associated with favorable
prognostic markers, beneficial patient outcome and
spontaneous regression. Elevated HOXC9 expression
levels strongly correlated with lower stages, ageo18 months
at diagnosis, lack of MYCN amplification, lack of 1p loss
and favorable gene expression-based classification22,23
(Figure 1a). Kaplan–Meier estimates were calculated by
Table 1 Prognostic classification of neuroblastoma patients using aHOX gene expression-based classifier: (a) Classification performance of the HOX classifier in the
training set; (b) Classification performance of the HOX classifier in 215 patients of the test set; and (c) Multivariate Cox regression models for the complete test set
based on EFS and OS, considering single prognostic markers and the HOX classifier
Classifier Patients (N) Probes (N) Accuracy (%) Sensitivity (%) Specificity (%)
(a)
NB_d75_hox52_fsPAM_pred 75 52 85 58 96
(b)
NB_d75_hox52_fsPAM_pred 215 40 76 63 90
Marker
Patients
(N)
Available cases
(N)
Hazard
ratio 95% CI P-value
(c)
Model considering single prognostic markers and the HOX classifier based
on EFS
574 547
Age (o18 months versus418 months) 2.06 1.48–2.87 o0.001
Stages (1–3, 4S versus 4) 1.49 1.49–2.07 0.018
MYCN (amplified versus normal) 1.44 1.44–2.03 0.041
HOX classifier (favorable versus unfavorable) 2.13 1.48–3.06 o0.001
Model considering single prognostic markers and the HOX classifier based
on OS
574 568
Age (o18 months versus418 months) 4.44 2.61–7.53 o0.001
Stages (1–3, 4S versus 4) 2.24 1.39–3.58 o0.001
MYCN (amplified versus normal) 2.62 1.77–3.88 o0.001
HOX classifier (favorable versus unfavorable) 3.1 1.67–5.76 o0.001
Abbreviation: CI, confidence interval
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using two independent neuroblastoma patient cohorts. The
first cohort consisted of 244 neuroblastoma patients, which
has been published previously by our group22 and has been
used by Mao and co-workers21 for clinical analysis of HOXC9
expression. This cohort was used to determine cutoff values
of HOXC9 expression levels by quartiles. The cutoff values
were applied on an independent set of 405 neuroblastoma
patients to determine clinical courses of patients with high,
intermediate–high, intermediate–low and low HOXC9 expres-
sions. Patients with high HOXC9 expression had a signifi-
cantly better outcome with a 5-year OS of 95±2% as
compared to patients with low HOXC9 expression (5-year
OS, 56±5%; Figure 1b). Likewise, HOXC9 expression levels
strongly correlated with improved EFS (high HOXC9 expres-
sion, 5-year EFS, 82±4% versus low HOXC9 expression,
5-year EFS, 37±5%; Figure 1c). In addition, multivariate Cox
regression models based on EFS and OS, considering
established risk markers (MYCN status, tumor stage and
patient age at diagnosis), determined HOXC9 expression as
a significant independent prognostic marker for both EFS and
OS (Table 2). We also investigated HOXC9 expression levels
in infant neuroblastoma that had regressed without any
chemotherapy, and compared these with infant stage 4
neuroblastoma. Notably, HOXC9 transcript levels were
significantly higher in neuroblastoma showing spontaneous
regression (Figure 1d and Supplementary Table S3). Taken
together, these results demonstrate that HOXC9 transcript
levels discriminate neuroblastoma patients with favorable and
unfavorable outcome and indicate that elevated HOXC9
expression is associated with spontaneous regression.
Elevated HOXC9 expression is associated with
abdominal neuroblastoma. As the expression of HOX
genes is not only temporally but also spatially regulated
during embryonic development, HOXC9 expression were
compared in neuroblastoma according to the primary tumor
site. We observed significantly higher HOXC9 expression
levels in tumors with abdominal location in comparison to
neuroblastomas located at the neck/chest or at adrenal
glands (Figure 1e), which is in line with the embryonal
expression pattern of HOX genes: HOX genes located
towards the 50 end of the HOX cluster, such as HOXC9,
Figure 1 (a) Association of HOXC9 expression with prognostic markers in 649 neuroblastomas as determined by microarray analysis. PAM classifier, gene expression-
based classifier as defined in the main text. Boxes, median expression values (horizontal line) and 25th and 75th percentiles; whiskers, distances from the end of the box to the
largest and smallest observed values that areo1.5 box lengths from either end of the box; open circles, outlying values; asterisks, extreme outlying values. (b) OS probability
in the validation set of neuroblastoma patients according to HOXC9 expression. (c) EFS probability in the validation set of neuroblastoma patients according to HOXC9
expression. (d) HOXC9 expression levels in spontaneously regressing and stage 4 infant neuroblastomas. (e) HOXC9 expression according to primary tumor localization.
Amp, amplification; norm, normal; aberr; aberration; fav, favorable; unfav, unfavorable; SR, spontaneously regressive; NK, neck; C, chest; ABD, abdomen; AG, adrenal gland;
Loc, localization
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are expressed more posterior in the body during develop-
ment. Analogous expression patterns, however, were
observed for only few of the remaining 50-located HOX
genes (Supplementary Figure S3a). Interestingly, the spatial
expression pattern of HOXC9 might not have been expected
from the association of primary tumor sites with patient
outcome.24,25 In line with these reports, we observed a better
outcome of patients with neck/chest neuroblastoma in
comparison to tumors located at the adrenal glands or in
the abdomen (neck/chest versus adrenal glands versus
abdomen, 5-year EFS, 84±5% versus 69±3% versus
63±4%, respectively; 5-year OS, 97±2% versus 83±2%
versus 85±3%, respectively; Supplementary Figures S3b
and S3c).
Numerical gain of chromosome 12 correlates with
elevated expression of HOXC9. We next aimed to evalu-
ate whether genetic or epigenetic aberrations of the HOXC9
locus are associated with deregulated HOXC9 expression.
First, we analyzed array-comparative genomic hybridiza-
tion (aCGH) profiles of 209 neuroblastoma samples and
compared the results with corresponding microarray
gene expression data of the same tumors. Genomic
aberrations of chromosome 12 were detected in 92/209
(44.0%) of the samples (Figure 2a and Supplementary
Table S4). We most frequently observed numerical gains
of the entire chromosome (n¼ 64, 30.6%). Numerical
chromosome 12 loss occurred only in four cases.
Segmental alterations of chromosome 12 were detected in
24 tumors (11.5%), most of which were segmental gains
not affecting the HOXC9 locus (n¼ 18, 8.6%). Analysis
of HOXC9 gene expression data revealed significantly
higher transcript levels in tumors with numerical
chromosome 12 gains in comparison to tumors in which
the HOXC9 locus was not affected by genomic alterations
(Figure 2b).
Table 2 Multivariate Cox regressionmodels based on EFS andOS considering age at diagnosis (418months versuso18months), stage (4 versus 1–3, 4S),MYCN
status (amplified versus normal) and HOXC9 expression (continuous)
Marker
Patients
(N)
Available
cases (N)
Hazard
ratio 95% CI P-value
Model considering single prognostic markers and HOXC9 expression based on EFS 649 622
Age (418 months versuso18 months) 0.48 0.34–0.66 o0.001
Stage (4 versus 1–3, 4S) 0.52 0.38–0.72 o0.001
MYCN (amplified versus normal) 0.57 0.42–0.79 0.001
HOXC9 expression (continuous) 0.75 0.60–0.93 0.012
Model considering single prognostic markers and HOXC9 expression based on OS 649 643
Age (418 months versuso18 months) 0.24 0.15–0.39 o0.001
Stage (4 versus 1–3, 4S) 0.33 0.26–0.52 o0.001
MYCN (amplified versus normal) 0.32 0.22–0.46 o0.001
HOXC9 expression (continuous) 0.73 0.55–0.97 0.03
Abbreviations: CI, confidence interval
Figure 2 Aberrations at chromosome 12 and correlation with HOXC9 expression. (a) Chromosomal aberrations of the HOXC9 locus in primary neuroblastomas (n¼ 200).
(b) Association of whole chromosome 12 gain with HOXC9 expression in primary neuroblastomas. Aberr, aberration; NG, numerical gain
Hox-C9 and spontaneous regression in neuroblastoma
H Kocak et al
4
Cell Death and Disease
To examinewhether inactivatingmutationsmight contribute
to diminished HOXC9 expression in neuroblastoma, we
sequenced the genomic HOXC9 locus of 46 primary tumors
with low HOXC9 expression. A total of 16 unique sequence
variants were detected (Supplementary Table S5). Eight of
these represented known SNPs, whereas the remaining
sequence variants were novel. The latter variants affected
either non-coding sequences or were synonymous, and
occurred infrequently in our cohort. Taken together, these
data suggest that mutations in the HOXC9 locus are not a
major cause of reduced HOXC9 expression levels in
unfavorable neuroblastoma.
To determine whether epigenetic regulation might con-
tribute to differences in HOXC9 expression in neuroblastoma,
we analyzed the methylation status of 26 CpG sites located in
the HOXC9 promoter region. DNA samples from 46 neuro-
blastoma tumorswith differingHOXC9 expression levels (high
and low HOXC9 expression as defined in Materials and
Methods, n¼ 23 per subgroup) and 2 neuroblastoma cell lines
(SK-N-AS and IMR-32) with loss of HOXC9 expression were
analyzed. Unsupervised one-way hierarchical clustering of
CpG site methylation revealed a largely homogeneous
methylation pattern in tumors of both subgroups and cell
lines (Supplementary Figure S4b), suggesting that down-
regulation of HOXC9 does not result from altered CpG
methylation patterns.
Doxycycline-inducible expression of Hox-C9 in neuro-
blastoma cell lines. HOXC9 expression was restored
in three neuroblastoma cell lines. Polyclonal Hox-C9-
expressing neuroblastoma cells were compared with poly-
clonal GFP-expressing cells (Figure 3a) due to promoter
leakage of the pRevTRE Vector System (Figure 3b).
Recombinant Hox-C9 protein levels were comparable to
physiological protein levels observed in neuroblastoma
patients with high Hox-C9 expression (Figure 3c).
HOXC9 expression inhibits growth of neuroblastoma
cells in vitro and in vivo. To investigate whether HOXC9
expression affects growth properties in neuroblastoma cells,
polyclonal HOXC9-expressing IMR-32, SK-N-AS and CHP-
212 cells were compared with polyclonal GFP-expressing
controls. Cell proliferation was assayed for up to 8 days using
Trypan blue dye exclusion tests. In all cell lines, the number
of viable cells at day 8 was significantly lower compared with
GFP-induced controls (Figure 4a). To determine whether
reduced proliferation upon HOXC9 re-expression might be
due to impaired cell cycle progression, the DNA content of
HOXC9-expressing cells was assessed by flow cytometry.
We observed a significant increase of the G0/G1 peak at day
7 after Hox-C9 induction in all three cell lines (Figure 4b). To
investigate the influence of HOXC9 on anchorage-indepen-
dent clonal growth, we preformed soft agar assays. A marked
reduction in colony formation was observed in both SK-N-AS
and IMR-32 cells in comparison to control cells (Figure 4c).
Two xenograft mouse model systems were used to assess
the effect of Hox-C9 on neuroblastoma tumor growth in vivo.
GFP-expressing SK-N-AS and IMR-32 control cells formed
rapidly growing tumors with mean tumor volumes of
1905±295mm3 at day 17 and 1323±404mm3 at day 22,
respectively. In contrast, tumor growth was almost comple-
tely abrogated in mice inoculated with HOXC9-expressing
SK-N-AS and IMR-32 (tumor volumes of 79±31mm3 at day
17 and 173±129mm3 at day 22, respectively; Figure 4d).
Hox-C9-induced neuronal differentiation of IMR-32
cells is accompanied by the downregulation of REST.
Morphological signs of neuronal differentiation were
assessed by microscopic examination in all three cell lines
after HOXC9 re-expression. In IMR-32 cells, HOXC9
re-expression led to a neuronal-like phenotype with a large
network of cells interconnected by long neurite elongations
(Figure 5a), while similar changes were not observed in the
Figure 3 Inducible expression of Hox-C9 in SK-N-AS, IMR-32 and CHP-212 cells and physiological Hox-C9 levels in primary neuroblastomas as determined by western
blot analysis. (a) Inducible expression of Hox-C9- versus GFP-expressing control cells. (b) Time course of Hox-C9 expression. (c) Representative neuroblastoma tumor
samples with high and low Hox-C9 expression. Dox, doxycycline; NB, neuroblastoma
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other cell lines. To determine whether this morphological
alteration induced by Hox-C9 was accompanied by the
upregulation of genes involved in neuronal differentiation, we
analyzed expression levels of the neuron-related markers
DNER, NTS, PTN, NNAT, TRKA and NEFL by quantitative
real-time reverse transcriptase-polymerase chain reactions
(qRT-PCR) and microarray analysis. In line with the
morphological changes, all markers were upregulated upon
HOXC9 re-expression (Figures 5b and c). A similar trend was
observed for additional markers associated with neuronal
differentiation (Supplementary Figure S5a and S5b). At the
same time, the RE1-silencing transcription factor REST, a
master negative regular of neurogenesis, was downregulated
in Hox-C9-induced IMR-32 cells (Figures 5d and e).
HOXC9 re-expression induces apoptosis in neuroblastoma
cells. We next examined whether apoptosis contributes to the
inhibition of neuroblastoma cell growth after HOXC9 re-
expression. First, externalization of phosphatidylserine was
analyzed by flow cytometry using Annexin-V staining. We
observed a significant increase of the Annexin-V-binding
fraction in SK-N-AS and CHP-212 cells 168h after HOXC9
re-expression in comparison to control cells (Figure 6a).
Second, DNA fragmentation was assessed using the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) assay in SK-N-AS, IMR-32 and CHP-212
cells. HOXC9-expressing neuroblastoma cells showed a
significantly higher fraction of apoptotic cells as compared with
GFP-expressing controls (Figure 6b). These results were
supported by FACS analysis following Hox-C9 induction in
SK-N-AS, IMR-32 and CHP-212 cells, in which Nicoletti labeling
and assessment of the fraction of sub-G1 events indicated an
accumulation of cells with fragmented DNA. In all investigated
cell lines, the number of apoptotic cells was significantly
increased by HOXC9 re-expression as compared with GFP-
induced controls (Figure 6c). Taken together, these findings
indicate that Hox-C9 affects growth properties in human
neuroblastoma cells not only by cell cycle regulation but also
by induction of apoptosis.
Hox-C9 activates the intrinsic pathway of apoptosis. To
further analyze Hox-C9-induced cell death, the expression of
pro- and antiapoptotic regulators was examined by immuno-
blot, qRT-PCR and microarray analysis. Apoptotic cell death
was associated with a strong increase of cytochrome c in the
cytosolic fraction of Hox-C9-induced cells (Figure 6d),
suggesting a loss of mitochondrial membrane potential and
involvement of mitochondria in Hox-C9-induced cell death. In
IMR-32 cells, we observed downregulation of BCL-2 both at
the transcript level and the protein level, while the expression
levels remained unchanged in SK-N-AS and CHP-212 cells
(Figures 6d–f). In the latter cell lines, however, we observed
a marked upregulation of BAX mRNA expression upon
induction of Hox-C9 (Figures 6e and f). These data suggest
that apoptosis induced by HOXC9 re-expression may be
conferred by a shifted BCL-2/BAX ratio as a consequence
of either increased expression of proapoptotic BAX or
decreased expression of antiapoptotic Bcl-2. Subsequently,
we investigated whether procaspase-9, the initial caspase in
the mitochondrial apoptotic cascade, is activated upon
Figure 4 HOXC9 re-expression inhibits growth of neuroblastoma cells in vitro and in vivo. Hox-C9-induced changes in (a) cell proliferation (Trypan blue dye exclusion
analysis), (b) cell cycle distribution (fluorescence-activated cell sorting (FACS)) and (c) soft agar colony formation. (d) Hox-C9 expression impede tumor growth in SK-N-AS
and IMR-32 neuroblastoma xenografts (n¼ 8 mice per group). Error bars indicate S.D.
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cytochrome c release. We observed an increase of cleaved
35 kDa fragments of activated caspase-9 in all cell lines upon
HOXC9 re-expression (Figure 6d). In addition, a 37 kDa
cleaved fragment of caspase-9 was observed in SK-N-AS
and CHP-212 cells (Figure 6d), which is indicative of a
feedback amplification loop induced by activated caspase-
3.26 Finally, we observed an increased activation of the
downstream effector caspase-3 and -7 in all three cell lines
(Figure 6d) upon HOXC9 re-expression. Taken together,
these data indicate that HOXC9 expression can activate the
intrinsic pathway of apoptosis and thereby trigger neuro-
blastoma cell death.
Hox-C9 affects transcriptional pathways regulating
differentiation and cell death. To gain further insights into
the molecular processes occurring upon HOXC9 re-expres-
sion, we analyzed gene expression profiles of IMR-32 and
SK-N-AS cells after Hox-C9 induction using microarrays. We
used gene ontology (GO) annotations to find classes of
genes that are significantly over-represented in gene sets
that were either up- or downregulated after HOXC9
re-expression (Supplementary Table S6). Many GO cate-
gories significantly enriched for genes upregulated in
HOXC9-expressing IMR-32 cells were related to neuronal
functions and differentiation, thereby reflecting the Hox-C9-
associated differentiation phenotype in IMR-32 cells
(Supplementary Table S6 and Supplementary Figure S7a).
In SK-N-AS cells, we observed GO categories significantly
enriched for genes upregulated by Hox-C9 that were
associated with cell death (Supplementary Table S6 and
Supplementary Figure S7c). These results are well in line
with the observed phenotypes of these two neuroblastoma
cell lines after HOXC9 re-expression: While growth inhibition
mediated by apoptosis is the predominant characteristic of
Figure 5 Hox-C9 induces neuronal differentiation in IMR-32 cells. (a) Morphological changes of IMR-32 cells upon Hox-C9 and GFP induction at day 21. HOXC9
expression upregulates neuron-related markers in IMR-32 cells as determined by (b) qRT-PCR and (c) oligonucleotide microarrays. Hox-C9 expression downregulates REST
as determined by (d) oligonucleotide microarrays and (e) qRT-PCR. Error bars indicate S.D.
Hox-C9 and spontaneous regression in neuroblastoma
H Kocak et al
7
Cell Death and Disease
HOXC9-expressing SK-N-AS cells, neuronal differentiation is
mainly observed in IMR-32 cells.
Discussion
In this study, we show that expression of the majority of class I
HOX genes is associated with clinical phenotypes of
neuroblastoma. HOX genes play essential roles in morpho-
genesis and cell differentiation during embryonic develop-
ment.1 As neuroblastoma is an embryonal tumor capable of
differentiating into ganglioneuroma or ganglioneuroblastoma,
it has been suggested that HOX transcription factors may be
involved in these processes.20,27 Accordingly, it has been
reported that morphological differentiation of neuroblastoma
cells upon treatment with RA is accompanied by an increase
of expression of a number of HOX genes.20,27,28 In line with
these results, we show here that the expression of most HOX
genes is significantly associated with prognostic markers and
clinical outcome in primary neuroblastoma, suggesting that
HOX genes are essentially involved in neuroblastoma
pathogenesis. The potential relevance of these genes is
further emphasized by the finding that a HOX gene expres-
sion-based classifier was able to predict accurately neuro-
blastoma patient outcome independently of age, stage and
Figure 6 Hox-C9 induces apoptosis in neuroblastoma cell lines by activating the intrinsic apoptotic pathway. (a) Proportion of Annexin-V-positive cells as determined by
fluorescence-activated cell sorting (FACS). (b) Proportion of cells showing apoptotic nuclei as determined by fluorescence microscopy. (c) Proportion of cells with subnormal
DNA content as determined by FACS. (d) Protein expression of Bcl-2, cytosolic cytochrome c and cleaved caspase-9, caspase-7 and caspase-3 upon Hox-C9 and GFP
induction as determined by western blot analysis (for densitometric quantification see Supplementary Figure S6). (e) BCL-2 and BAX expression in IMR-32 and SK-N-AS cells
following Hox-C9 induction as determined by microarrays. (f) BCL-2 expression in IMR-32 cells, and BAX expression in SK-N-AS and CHP-212 cells following Hox-C9
induction as determined by qRT-PCR. Error bars indicate S.D. Dox, doxycycline
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MYCN status. We observed thatHOX genes of the A, B and C
clusters were mainly upregulated in favorable neuroblastoma,
while genes of the D cluster, particularly HOXD3, HOXD8,
HOXD9 and HOXD10, were upregulated in unfavorable
tumors. These findings are in contrast to a recent study of
Mao et al.,21 who investigated the prognostic values of a panel
of HOX genes in primary neuroblastoma, and did not observe
any correlation of expression and clinical outcome for most of
these. The difference between the two studies might be
explained by the fact that Mao and co-workers21 had
examined a limited number of samples comprising metasta-
sized neuroblastoma without MYCN amplification only,29
while a large tumor cohort representing the entire spectrum
of the disease has been analyzed in our study.
Among all HOX genes, HOXC9 expression was most
prominently associated with favorable prognostic markers
and with clinical outcome. The prognostic impact ofHOXC9 is
underlined by the fact that this gene was selected in all
predictive models generated during the training phase of the
process of HOX classifier generation, and that it was one of
144 genes of a prognostic classifier that we have reported
previously.22 Using gene expression data from our group and
others, HOXC9 expression has in addition been described to
be associated with the clinical neuroblastoma phenotype in a
recent study.21 Notably, we observed thatHOXC9 expression
levels were higher in neuroblastomas, which had sponta-
neously regressed than in age-related stage 4 tumors,
suggesting that this transcription factor might be involved in
the enigmatic molecular process of spontaneous regression.
Spatial and temporal colinearity is a hallmark of clustered
HOX genes.30,31 HOX genes that are positioned closer to the
50 end of the cluster, such asHOXC9, are expressed later and
more posterior during early development. In accordance with
the embryonic expression pattern of HOX genes, we here
show a significant correlation of increasedHOXC9 expression
levels of neuroblastomas from abdominal sites in comparison
to tumors of the neck and chest. This finding contrasts with
previous speculations,21 which suggested that HOXC9
expression might be higher in tumors of the neck and thorax
because of their association with a better outcome24,25 and a
more differentiated histology.32
We next questioned which genetic or epigenetic factors
might influence HOXC9 expression in primary neuroblas-
toma. A gain of chromosome 12, which comprises theHOXC9
locus, was associated with elevated HOXC9 transcript levels,
suggesting that a gene–dosage effect might account for
HOXC9 expression differences in neuroblastoma. These
findings are in line with previous reports showing that
numerical chromosomal aberrations, including chromosome
12 gain,33,34 are associated with lower stages35 and better
outcome in neuroblastoma.36 By contrast, we neither
detected hypermethylation of the promoter region of HOXC9
nor inactivating mutations in the HOXC9 locus as a potential
cause of diminished HOXC9 expression in unfavorable
tumors. Alternatively, other mechanisms, such as regulatory
RNAs37 or upstream transcriptional regulators,19 may control
HOXC9 expression in neuroblastoma.
In line with data reported by Mao et al.,21 we observed
reduced proliferation and cell cycle arrest in the G0/G1 phase
upon HOXC9 re-expression. Moreover, we substantiate that
Hox-C9 may induce neuronal differentiation in a fraction of
neuroblastomas. In addition, we observed downregulation of
REST after HOXC9 re-expression. REST is a well-known
master negative regulator of neurogenesis,38 and has been
reported to be degraded uponRA-induced neuroblastoma cell
differentiation.39 Taking these findings together, it seems
likely that Hox-C9 promotes a more differentiated neuroblas-
toma phenotype by the downregulation of REST.
The strong effect of Hox-C9 re-expression on neuroblas-
toma growth arrest observed by us and others21 suggested
that other mechanisms than cell cycle arrest alone may
contribute to this phenotype. Accordingly, we here provide
substantial evidence that Hox-C9 promotes apoptosis in
neuroblastoma in general, as indicated by a strong increase
in the sub-G1 fraction and an increase in TUNEL-positive cells
after Hox-C9 induction in all three cell lines. We demonstrate
that HOXC9 expression activates the intrinsic pathway of
apoptosis, probably by increasing the BAX:BCL-2 ratio, which
in turn leads to the release of cytochrome c from the
mitochondria into the cytosol and activates the intrinsic
cascade of caspases. Delayed activation of the naturally
occurring process of programmed cell death during develop-
ment of the peripheral nervous system has been suggested to
represent the molecular basis of spontaneous regression in
neuroblastoma.11,12 Taking the correlation of HOXC9 expres-
sion with favorable outcome and spontaneous regression in
neuroblastoma, its developmental significance and its proa-
poptotic function in neuroblastoma cells into account, we
hypothesize that Hox-C9 may contribute to the process of
spontaneous regression in neuroblastoma.
In summary, we here demonstrate that distinct HOX gene
expression patterns are associated with clinical phenotypes of
neuroblastoma. We show that HOXC9 expression does not
only correlate with favorable prognostic markers and bene-
ficial clinical outcome but also with spontaneous regression in
infant neuroblastoma. Re-expression of HOXC9 in neuro-
blastoma cell lines consistently leads to strong growth arrest
and activates the intrinsic pathway of apoptosis. Taken
together, we conclude from our data that HOX genes may
contribute to neuroblastoma pathogenesis, and that Hox-C9
might be involved in the molecular process of spontaneous
regression.
Materials and Methods
Patient characteristics. Tumors of 649 neuroblastoma patients were
analyzed. Stages were classified according to the International Neuroblastoma
Staging System:40 stage 1, n¼ 153; stage 2, n¼ 113; stage 3, n¼ 91;
stage 4, n¼ 214; and stage 4S, n¼ 78. Primary tumors were localized in the
abdomen (n¼ 135), at the neck/chest (n¼ 69) or the adrenal glands (n¼ 276).
The primary tumor localization for the remaining 169 patients was unknown.
The subgroup of patients showing regression of neuroblastoma consisted of 43
infants (localized, n¼ 14; stage 4S, n¼ 29), in which the tumor manifestations
showed unambiguous regression without any cytotoxic treatment.41 The
neuroblastoma subgroups used for methylation and aCGH analyses consisted
of 46 and 209 tumors, respectively. Risk estimation of corresponding patients
was performed according to the International Neuroblastoma Risk Group
(INRG) classification system42 (methylation: high risk, n¼ 21; intermediate and
low risk, n¼ 24; unclassified, n¼ 1; aCGH: high risk, n¼ 56; intermediate and
low risk, n¼ 153).
Gene expression analysis. Single-color gene expression profiles from 649
neuroblastoma tumors and 2 neuroblastoma cell lines were generated using 44K
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oligonucleotide microarrays as described previously.43 Total RNA of HOXC9- and
GFP-expressing SK-N-AS and IMR-32 cells was isolated at 0, 6, 12, 24, 48 and
96 h using Trizol (Invitrogen, Karlsruhe, Germany). To determine global
differences in the expression profiles of HOXC9- and GFP-induced SK-N-AS
and IMR-32 cells, mean expression levels of each gene between HOXC9-induced
and control cells were compared. Gene Ontology Tree Machine (GOTM)44 was
used to identify functional categories associated with the condition of the
respective cell line (Supplementary Materials and Methods). All raw and
normalized microarray data are available through the Gene Expression Omnibus
database (Accession: GSE45480).
HOX gene expression-based classification. To develop a HOX gene
expression-based classifier (HOX classifier), the nearest shrunken centroids
method (PAM)45 was applied on HOX gene expression data from 75
neuroblastoma patients with maximal divergent clinical outcome.22 Classification
performance in the training set was evaluated by a 10 times repeated 5-fold cross-
validation. Probes that were included in at least 65% of all cross-validation models
were selected as classifier probes.22 Classification accuracy of the final HOX
classifier comprising 33 HOX genes was assessed in an independent validation
set of 574 neuroblastoma patients using the support vector machine (SVM)46
algorithm. Multivariate Cox proportional hazard models based on EFS and OS
were used to analyze the prognostic impact of this classifier. The factors age
(o18 months versus 418 months), tumor stage (stages 1–3 and 4S versus
stage 4), MYCN (normal versus amplified) and HOX classifier were fitted into a
stepwise-backward selection model.
Analysis of genetic aberrations and promoter methylation of
HOXC9. Oligonucleotide aCGH profiles from 209 neuroblastoma tumors
were generated using 44K, 105K or 1M microarrays as described previously.35,47
Array-CGH analysis was preformed as described previously47 and visualized
using the Integrative Genomics Viewer.48 Because of technical reasons, 9 out
of 209 aCGH profiles could not be visualized. Array-CGH data are available
at Gene Expression Omnibus (Accession: GSE25771 and GSE45480). HOXC9
promoter methylation analysis was performed by Sequenom Inc. (Hamburg,
Germany; Supplementary Materials and Methods and Supplementary Table S5).
Whole genome-amplified DNA from primary neuroblastoma specimens and
neuroblastoma cell lines were used to sequence amplicons covering the first 500
nucleotides upstream of the HOXC9 start site, 50- and 30-UTRs and the complete
coding region with exon–intron boundaries. Sequencing was performed by
Beckman Coulter Genomics (Danvers, MA, USA; Supplementary Materials and
Methods and Supplementary Table S5).
Data analysis and statistics. Statistical analysis of associations between
HOX mRNA expression levels and neuroblastoma subgroups, prognostic markers
and outcome in neuroblastoma was performed using SPSS version 20.0 (IBM,
Mainz, Germany). Two-tailed non-parametric tests (Mann–Whitney U-test and
Kruskal–Wallis test) were used where appropriate. All HOX genes were first tested
in a univariable Cox regression model based on OS and EFS. For all HOX genes
with P-values r0.05, the whole cohort (n¼ 649) was divided using quartiles
based on HOX gene expression levels. Kaplan–Meier estimates for OS (n¼ 649)
and EFS (n¼ 628) were compared by log-rank test. In addition, HOXC9 was
investigated separately by using quartile values of HOXC9 expression levels in a
set of 244 neuroblastoma tumors. These values were applied on an independent
set of 405 neuroblastoma expression profiles as a cutoff for high, intermediate–
high, intermediate–low and low HOXC9 expressions. Kaplan–Meier estimates for
OS (n¼ 405) and EFS (n¼ 384) were compared by log-rank test. Recurrence,
progression and death from disease were considered as events. Multivariate Cox
proportional hazard models based on EFS and OS were used to analyze the
prognostic impact of HOXC9 expression in neuroblastoma. The factors age (418
months versus o18 months), tumor stage (stage 4 versus stages 1–3 and 4S),
MYCN (amplified versus normal) and HOXC9 expression were fitted into a
stepwise-backward selection model. The likelihood ratio test P for inclusion was
r0.05 and for exclusion was 40.05. Quantitative data for functional analysis
were shown as means±S.D. Unpaired two-tailed Student’s t-tests were used
where appropriate.
Cell culture. SK-N-AS and CHP-212 cells were obtained from ATCC
(Manassas, VA, USA) and IMR-32 cells were purchased from German Collection
of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany).
Neuroblastoma cell lines were authenticated at the DSMZ. Cells were maintained
as described in Supplementary Materials and Methods.
Retroviral plasmids and stable inducible neuroblastoma cell
lines. A human HOXC9 full open reading frame was obtained from the retroviral
vector pBIG2rHOXC9 (kind gift of Malte Buchholz, Philipps-University of Marburg,
Marburg, Germany) and cloned into the pRevTRE vector (Clontech, Heidelberg,
Germany; Supplementary Materials and Methods). Polyclonal neuroblastoma cell
lines stably expressing either HOXC9 or GFP under the control of the reverse
tetracycline-controlled transactivator were generated using the RevTet System
(Clontech) according to the manufacturer’s instructions with marginal modifications
(Supplementary Materials and Methods).
Expression analyses using immunoblots and qRT-PCR.
Immunoblots were prepared as described previously.49 Cytosolic cell extracts
were isolated as described elsewhere.50 Total protein extracts were isolated either
with RIPA or Cell Lysis Buffer (Biovision, Hannover, Germany). Densitometric
quantification of immunoblots was performed using the Image J software (NIH,
Bethesda, MD, USA).51 qRT-PCR was carried out two times in duplicates as
described previously.52 Antibody and primer information is given in Supplementary
Materials and Methods and Supplementary Table S5, respectively.
In vitro growth assays. Cell viability was analyzed by Trypan blue dye
exclusion (Supplementary Materials and Methods) and cell cycle distribution was
assessed by FACS analysis as described previously.53
Tumorigenicity assays. Soft agar assays were used to assess the effect of
HOXC9 on colony formation ability of neuroblastoma cells (Supplementary
Materials and Methods). A total of 32 six-week-old female athymic nude-Foxn1nu
mice (Harlan Laboratories, Horst, The Netherlands) were used for the
establishment of neuroblastoma xenograft tumors (Supplementary Materials and
Methods).
Cell viability analysis. The TUNEL analysis was performed using the In Situ
Cell Death Detection Kit according to the manufacturer’s protocol (Roche,
Mannheim, Germany; Supplementary Materials and Methods). Annexin-V-binding
analysis was carried out using APC-coupled Annexin-V and 7-AAD according to
the manufacturer’s protocol (BD Biosciences, Heidelberg, Germany). Apoptotic
cells were detected by FACS (FACS Canto; BD Biosciences) using the DIVA
software (BD Biosciences). The extent of DNA fragmentation was evaluated in a
hypoploidy assay as described elsewhere.54
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